

Tetsuo Shoji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9073623/publications.pdf>

Version: 2024-02-01

122
papers

7,206
citations

47006

47
h-index

58581

82
g-index

126
all docs

126
docs citations

126
times ranked

6630
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes Mellitus, Aortic Stiffness, and Cardiovascular Mortality in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2001, 12, 2117-2124.	6.1	390
2	Brachial-Ankle Pulse Wave Velocity and the Risk Prediction of Cardiovascular Disease. Hypertension, 2017, 69, 1045-1052.	2.7	382
3	Lower risk for cardiovascular mortality in oral 1 $\hat{\text{A}}$ -hydroxy vitamin D3 users in a haemodialysis population. Nephrology Dialysis Transplantation, 2004, 19, 179-184.	0.7	346
4	Insulin Resistance as an Independent Predictor of Cardiovascular Mortality in Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 1894-1900.	6.1	339
5	Clinical Practice Guideline for the Management of Chronic Kidney Disease $\hat{\text{A}}$ Mineral and Bone Disorder. Therapeutic Apheresis and Dialysis, 2013, 17, 247-288.	0.9	305
6	High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney International, 1995, 48, 820-826.	5.2	284
7	The heart and vascular system in dialysis. Lancet, The, 2016, 388, 276-284.	13.7	219
8	Preferential Stiffening of Central Over Peripheral Arteries in Type 2 Diabetes. Diabetes, 2003, 52, 448-452.	0.6	202
9	Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis. Diabetes Care, 2006, 29, 1496-1500.	8.6	176
10	Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis, 2000, 148, 171-177.	0.8	161
11	Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney International, 2002, 61, 2187-2192.	5.2	146
12	Serum Phosphate and Calcium Should Be Primarily and Consistently Controlled in Prevalent Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2013, 17, 221-228.	0.9	133
13	Overview of Regular Dialysis Treatment in $\langle\text{scp}\rangle\langle\text{scp}\rangle\text{apan}$ (as of 31 $\langle\text{scp}\rangle\text{D}\langle\text{scp}\rangle\text{ecember}$ 2011). Therapeutic Apheresis and Dialysis, 2013, 17, 567-611.	0.9	132
14	Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. American Journal of Kidney Diseases, 2003, 41, S76-S79.	1.9	129
15	Antibodies Against Oxidized LDL and Carotid Artery Intima-Media Thickness in a Healthy Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 703-707.	2.4	120
16	Arterial stiffness in predialysis patients with uremia. Kidney International, 2004, 65, 936-943.	5.2	119
17	Pulse Wave Velocity in Lower-Limb Arteries among Diabetic Patients with Peripheral Arterial Disease.. Journal of Atherosclerosis and Thrombosis, 2003, 10, 253-258.	2.0	116
18	Impaired metabolism of high density lipoprotein in uremic patients. Kidney International, 1992, 41, 1653-1661.	5.2	111

#	ARTICLE	IF	CITATIONS
19	Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 387-435.	0.9	109
20	Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. <i>Atherosclerosis</i> , 1997, 131, 229-236.	0.8	108
21	Regional Arterial Stiffness in Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2245-2252.	6.1	108
22	Elevated Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Predicts Atherosclerotic Cardiovascular Events in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1112-1120.	4.5	105
23	Fatigue Is a Predictor for Cardiovascular Outcomes in Patients Undergoing Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 659-666.	4.5	96
24	Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis. <i>BMC Nephrology</i> , 2019, 20, 105.	1.8	85
25	Angiotensin-Converting Enzyme Gene Polymorphism Is Associated With Carotid Arterial Wall Thickness in Non-Insulin-Dependent Diabetic Patients. <i>Circulation</i> , 1996, 94, 704-707.	1.6	85
26	Paradox of risk factors for cardiovascular mortality in uremia: Is a higher cholesterol level better for atherosclerosis in uremia?. <i>American Journal of Kidney Diseases</i> , 2001, 38, S4-S7.	1.9	83
27	HOMA Index to Assess Insulin Resistance in Renal Failure Patients. <i>Nephron</i> , 2001, 89, 348-349.	1.8	79
28	Central versus peripheral arterial stiffness in association with coronary, cerebral and peripheral arterial disease. <i>Atherosclerosis</i> , 2010, 211, 480-485.	0.8	78
29	Effect of Atorvastatin on Regional Arterial Stiffness in Patients with Type 2 Diabetes Mellitus. <i>Journal of Atherosclerosis and Thrombosis</i> , 2005, 12, 205-210.	2.0	76
30	Femoral artery wall thickness and stiffness in evaluation of peripheral vascular disease in type 2 diabetes mellitus. <i>Atherosclerosis</i> , 2001, 158, 207-214.	0.8	74
31	Atherogenic lipoproteins in end-stage renal disease. <i>American Journal of Kidney Diseases</i> , 2001, 38, S30-S33.	1.9	73
32	Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. <i>Kidney International</i> , 2003, 63, S117-S120.	5.2	69
33	Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 299-315.	2.0	67
34	Serum n-3 and n-6 Polyunsaturated Fatty Acid Profile as an Independent Predictor of Cardiovascular Events in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2013, 62, 568-576.	1.9	66
35	Renal insufficiency accelerates atherosclerosis in patients with type 2 diabetes mellitus. <i>American Journal of Kidney Diseases</i> , 2001, 38, S186-S190.	1.9	60
36	Additive impacts of diabetes and renal failure on carotid atherosclerosis. <i>Atherosclerosis</i> , 2000, 153, 257-258.	0.8	59

#	ARTICLE	IF	CITATIONS
37	Cerebral microbleeds in predialysis patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1554-1559.	0.7	59
38	Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. <i>Atherosclerosis</i> , 2009, 202, 582-588.	0.8	58
39	Arterial stiffness predicts cardiovascular death independent of arterial thickness in a cohort of hemodialysis patients. <i>Atherosclerosis</i> , 2010, 210, 145-149.	0.8	57
40	Increasing Body Fat Mass in the First Year of Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1921-1926.	6.1	56
41	Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2325.	7.4	55
42	Association between Plasma Angiotensin-Like Protein 3 and Arterial Wall Thickness in Healthy Subjects. <i>Journal of Vascular Research</i> , 2007, 44, 61-66.	1.4	54
43	Effect of Chair Stand Exercise on Activity of Daily Living: A Randomized Controlled Trial in Hemodialysis Patients. , 2015, 25, 17-24.		52
44	Poor muscle quality as a predictor of high mortality independent of diabetes in hemodialysis patients. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 266-270.	5.6	50
45	Association of Endothelial and Vascular Smooth Muscle Dysfunction with Cardiovascular Risk Factors, Vascular Complications, and Subclinical Carotid Atherosclerosis in Type 2 Diabetic Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 276-284.	2.0	50
46	Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 379-386.	1.6	49
47	Roles of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis. <i>Metabolism: Clinical and Experimental</i> , 1991, 40, 1002-1008.	3.4	48
48	Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. <i>Kidney International</i> , 2002, 62, 2230-2237.	5.2	48
49	Arterial wall stiffness is associated with peripheral circulation in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2003, 170, 87-91.	0.8	48
50	Cross-Sectional Association of Serum Phosphate With Carotid Intima-Medial Thickness in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 859-865.	1.9	46
51	Altered relationship between body fat and plasma adiponectin in end-stage renal disease. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 330-334.	3.4	46
52	Regional Arterial Stiffness Associated with Ischemic Heart Disease in Type 2 Diabetes Mellitus. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 114-121.	2.0	45
53	Chronic Kidney Disease as a Metabolic Syndrome with Malnutrition-Need for Strict Control of Risk Factors. <i>Internal Medicine</i> , 2005, 44, 179-187.	0.7	42
54	A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome. <i>Nephron Extra</i> , 2015, 5, 58-66.	1.1	41

#	ARTICLE	IF	CITATIONS
55	Lipopolysaccharide-binding protein is associated with arterial stiffness in patients with type 2 diabetes: a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2017, 16, 62.	6.8	38
56	Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 996-1001.	3.4	36
57	Ankle-brachial index measured by oscillometry is predictive for cardiovascular disease and premature death in the Japanese population: An individual participant data meta-analysis. <i>Atherosclerosis</i> , 2018, 275, 141-148.	0.8	34
58	Association of Zinc Deficiency with Development of CVD Events in Patients with CKD. <i>Nutrients</i> , 2021, 13, 1680.	4.1	33
59	Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2014, 13, 10.	6.8	32
60	Cerebral Microbleeds Predict Intracerebral Hemorrhage in Hemodialysis Patients. <i>Stroke</i> , 2015, 46, 2107-2112.	2.0	31
61	Plasma omentin levels are associated with vascular endothelial function in patients with type 2 diabetes at elevated cardiovascular risk. <i>Diabetes Research and Clinical Practice</i> , 2019, 148, 160-168.	2.8	31
62	Plasma Lipoprotein Abnormalities in Hemodialysis Patients—Clinical Implications and Therapeutic Guidelines. <i>Therapeutic Apheresis and Dialysis</i> , 2006, 10, 305-315.	0.9	30
63	Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 685-693.	1.6	29
64	Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 409-417.	2.0	29
65	Decreased Albuminuria by Pravastatin in Hyperlipidemic Diabetics. <i>Nephron</i> , 1991, 59, 664-665.	1.8	26
66	Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: Effect of a fibric acid, cinofibrate. <i>Kidney International</i> , 1993, 44, 1352-1359.	5.2	26
67	Active Vitamin D and Acute Respiratory Infections in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1361-1367.	4.5	26
68	Decreased serum adrenal androgen dehydroepiandrosterone sulfate and mortality in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3915-3922.	0.7	26
69	Plasma omentin levels are inversely associated with atherosclerosis in type 2 diabetes patients with increased plasma adiponectin levels: a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2019, 18, 167.	6.8	26
70	Plasma polyunsaturated fatty acid profile and delta-5 desaturase activity are altered in patients with type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1432-1438.	3.4	25
71	The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients. <i>Kidney International</i> , 2003, 63, S128-S130.	5.2	24
72	Cardiothoracic Ratio as a Predictor of Cardiovascular Events in a Cohort of Hemodialysis Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 412-421.	2.0	24

#	ARTICLE	IF	CITATIONS
73	Serum C-reactive protein and thioredoxin levels in subjects with mildly reduced glomerular filtration rate. BMC Nephrology, 2010, 11, 7.	1.8	22
74	Simultaneously Measured Interarm Blood Pressure Difference and Stroke. Hypertension, 2018, 71, 1030-1038.	2.7	22
75	Oxidative Stress and Inflammation as Predictors of Mortality and Cardiovascular Events in Hemodialysis Patients: The DREAM Cohort. Journal of Atherosclerosis and Thrombosis, 2021, 28, 249-260.	2.0	21
76	Disappearance of Association in Diabetic Patients on Hemodialysis between Anemia and Mortality Risk: The Japan Dialysis Outcomes and Practice Pattern Study. Nephron Clinical Practice, 2012, 120, c91-c100.	2.3	20
77	Advantage of Insulin Glulisine Over Regular Insulin in Patients With Type 2 Diabetes and Severe Renal Insufficiency. , 2015, 25, 129-134.		19
78	Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 599-612.	4.5	19
79	Body fat mass in hemodialysis patients. American Journal of Kidney Diseases, 2003, 41, S137-S141.	1.9	18
80	Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia. Atherosclerosis, 2009, 207, 579-584.	0.8	18
81	Roles of metabolic and endocrinological alterations in atherosclerosis and cardiovascular disease in renal failure: Another form of metabolic syndrome. Seminars in Nephrology, 2004, 24, 423-425.	1.6	16
82	Use of Vitamin D Receptor Activator, Incident Cardiovascular Disease and Death in a Cohort of Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2015, 19, 235-244.	0.9	16
83	Plasma C1q/TNF-Related Protein-9 Levels Are Associated with Atherosclerosis in Patients with Type 2 Diabetes without Renal Dysfunction. Journal of Diabetes Research, 2016, 2016, 1-9.	2.3	16
84	Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney International, 1999, 56, S134-S136.	5.2	15
85	Molecular forms of adiponectin in uraemic plasma. Nephrology Dialysis Transplantation, 2004, 19, 1937-1938.	0.7	15
86	Plasma soluble leptin receptor levels are associated with pancreatic β -cell dysfunction in patients with type 2 diabetes. Journal of Diabetes Investigation, 2018, 9, 55-62.	2.4	15
87	Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis. BMC Nephrology, 2021, 22, 104.	1.8	15
88	Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrology Dialysis Transplantation, 2008, 23, 2329-2336.	0.7	14
89	Effect of Diabetes on Uremic Dyslipidemia.. Journal of Atherosclerosis and Thrombosis, 2002, 9, 305-313.	2.0	14
90	Body Composition and Cardiovascular Risk in Hemodialysis Patients. , 2006, 16, 241-244.		13

#	ARTICLE	IF	CITATIONS
91	Visceral Adiposity is Preferentially Associated with Vascular Stiffness Rather than Thickness in Men with Type 2 Diabetes. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 1067-1079.	2.0	13
92	Plasma homocysteine and cerebral small vessel disease as possible mediators between kidney and cognitive functions in patients with diabetes mellitus. <i>Scientific Reports</i> , 2017, 7, 4382.	3.3	12
93	Inter-Arm Blood Pressure Difference in Diabetes Mellitus and Its Preferential Association with Peripheral Artery Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 780-788.	2.0	11
94	Low Free Triiodothyronine Level as a Predictor of Cardiovascular Events and All-Cause Mortality in Patients Undergoing Hemodialysis: The DREAM Cohort. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 1071-1082.	2.0	11
95	Secondary Hyperparathyroidism, Decreased Hepatic Triglyceride Lipase, Elevated Intermediate Density Lipoprotein and Atherosclerosis in Hemodialysis Patients. <i>Nephron</i> , 1998, 78, 121-122.	1.8	9
96	Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 257-260.	1.6	9
97	Silent Cerebral Microbleeds and Longitudinal Risk of Renal and Cardiovascular Events in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1557-1565.	4.5	9
98	Steno-Stiffness Approach for Cardiovascular Disease Risk Assessment in Primary Prevention. <i>Hypertension</i> , 2019, 73, 508-513.	2.7	9
99	Association between Serum Zinc and Calcification Propensity (T50) in Patients with Type 2 Diabetes Mellitus and In Vitro Effect of Exogenous Zinc on T50. <i>Biomedicines</i> , 2020, 8, 337.	3.2	9
100	Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000265.	2.8	8
101	Nutritional Disorder Evaluated by the Geriatric Nutritional Risk Index Predicts Death After Hospitalization for Infection in Patients Undergoing Maintenance Hemodialysis. , 2022, 32, 751-757.		8
102	Effects of the Nicotinic Acid Analogue Niceritrol on Lipoprotein Lp(a) and Coagulation-Fibrinolysis Status in Patients with Chronic Renal Failure on Hemodialysis. <i>Nephron</i> , 1997, 77, 112-113.	0.6	7
103	Endocrine and Metabolic Changes Affecting Cardiovascular Disease in Dialysis Patients. , 2015, 25, 223-225.		6
104	Vitamin D receptor activator and prevention of cardiovascular events in hemodialysis patientsâ€™ rationale and design of the Japan Dialysis Active Vitamin D (J-DAVID) trial. <i>Renal Replacement Therapy</i> , 2016, 2, .	0.7	6
105	Altered Serum n-6 Polyunsaturated Fatty Acid Profile and Risks of Mortality and Cardiovascular Events in a Cohort of Hemodialysis Patients. , 2018, 28, 54-63.		6
106	Difficulty in activities of daily living and falls in patients undergoing hemodialysis: A cross-sectional study with nondialysis controls. <i>Hemodialysis International</i> , 2021, 25, 338-347.	0.9	6
107	Association of Reduced Free T3 to Free T4 Ratio with Lower Serum Creatinine in Japanese Hemodialysis Patients. <i>Nutrients</i> , 2021, 13, 4537.	4.1	6
108	Plasma polyunsaturated fatty acid profile is associated with vascular endothelial function in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 352-355.	2.0	5

#	ARTICLE	IF	CITATIONS
109	Associations of cardiovascular disease and blood pressure with cognition in hemodialysis patients: The Osaka Dialysis Complication Study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1758-1767.	0.7	4
110	Does paricalcitol reduce proteinuria in patients with chronic kidney disease?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 352-353.	2.0	3
111	Reverse epidemiology in hemodialysis patients. Lessons from Japanese registries. <i>Nephrologie Et Therapeutique</i> , 2008, 4, 223-227.	0.5	3
112	Current Focuses in Serum Lipid Abnormalities in Dialysis Patients. <i>Blood Purification</i> , 2015, 40, 326-331.	1.8	3
113	Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 220-228.	0.9	3
114	Body fat measurement in chronic kidney disease: implications in research and clinical practice. <i>Current Opinion in Nephrology and Hypertension</i> , 2007, 16, 572-576.	2.0	2
115	Associations of Serum Insulin-Like Growth Factor 1 with New Cardiovascular Events and Subsequent Death in Hemodialysis Patients: The DREAM Cohort. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 1153-1165.	2.0	2
116	Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS). <i>Nutrients</i> , 2022, 14, 343.	4.1	2
117	Thrice-weekly insulin injection with nurse's support for diabetic hemodialysis patients having difficulty with self injection. <i>Osaka City Medical Journal</i> , 2012, 58, 35-8.	0.4	2
118	Vitamin D, Cardiovascular System, and Longevity of Hemodialysis Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2006, 10, S27-S33.	0.9	1
119	Role of adiponectin in the relationship between visceral adiposity and fibroblast growth factor 23 in non-diabetic men with normal kidney function. <i>Endocrine Journal</i> , 2022, 69, 121-129.	1.6	1
120	1. ä;ä~æœÿè...Žä,ä...ã«ãšãã,ã«è,,^çj-ãCE-ã@ãšé†è©•ã¼j. <i>Nihon Toseki Igakkai Zasshi</i> , 2007, 40, 130-131.	0.1	1
121	Response to comment on Imamura et al. Plasma polyunsaturated fatty acid profile and delta-5 desaturase activity are altered in patients with type 2 diabetes. <i>Metabolism</i> 2014;63(11):1432-8. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, e3-e4.	3.4	0
122	ĩ¼“ĩ¼Ž è,,è³ã½Žä,è--ã«ã,ã,éœžœ,èè...ã@ã«è,,^çj-ãCE-æ€Sã,ãf™ãf³ãf^æS^ã^¶. <i>Nihon Toseki Igakkai Zasshi</i> , 2011, 44, 1136-113		